Literature DB >> 10645003

Inhibition of collagenase-3 (MMP-13) expression in transformed human keratinocytes by interferon-gamma is associated with activation of extracellular signal-regulated kinase-1,2 and STAT1.

R Ala-aho1, N Johansson, R Grénman, N E Fusenig, C López-Otín, V M Kähäri.   

Abstract

Collagenase-3 (MMP-13) is characterized by an exceptionally wide substrate specificity and restricted expression. MMP-13 is specifically expressed by transformed human keratinocytes in squamous cell carcinomas in vivo and its expression correlates with their invasion capacity. Here, we show, that interferon-gamma (IFN-gamma) markedly inhibits expression of MMP-13 by human cutaneous SCC cells (UT-SCC-7) and by ras-transformed human epidermal keratinocytes (A-5 cells) at the transcriptional level. In addition, IFN-gamma inhibits collagenase-1 (MMP-1) expression in these cells. IFN-gamma abolished the enhancement of MMP-13 and MMP-1 expression by transforming growth factor-beta (TGF-beta) and tumor necrosis factor-alpha (TNF-alpha), and inhibited invasion of A-5 cells through type I collagen. IFN-gamma also rapidly and transiently activates extracellular signal-regulated kinase 1,2 (ERK1,2) and blocking ERK1,2 pathway (Raf/MEK1,2/ERK1,2) by specific MEK1,2 inhibitor PD98059 partially (by 50%) prevents Ser-727 phosphorylation of STAT1 and suppression of MMP-13 expression by IFN-gamma. Furthermore, Ser-727 phosphorylation of STAT1 by ERK1,2, or independently of ERK1,2 activation is associated with marked reduction in MMP-13 expression. These observations identify a novel role for IFN-gamma as a potent inhibitor of collagenolytic activity and invasion of transformed squamous epithelial cells, and show that inhibition of MMP-13 expression by IFN-gamma involves activation of ERK1,2 and STAT1.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10645003     DOI: 10.1038/sj.onc.1203306

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  7 in total

1.  Serpin peptidase inhibitor clade A member 1 (SerpinA1) is a novel biomarker for progression of cutaneous squamous cell carcinoma.

Authors:  Mehdi Farshchian; Atte Kivisaari; Risto Ala-Aho; Pilvi Riihilä; Markku Kallajoki; Reidar Grénman; Juha Peltonen; Taina Pihlajaniemi; Ritva Heljasvaara; Veli-Matti Kähäri
Journal:  Am J Pathol       Date:  2011-07-01       Impact factor: 4.307

2.  Epithelial to mesenchymal transition in gingival overgrowth.

Authors:  Siddika Selva Sume; Alpdogan Kantarci; Alan Lee; Hatice Hasturk; Philip C Trackman
Journal:  Am J Pathol       Date:  2010-05-20       Impact factor: 4.307

Review 3.  Regulation and Function of Matrix Metalloproteinase-13 in Cancer Progression and Metastasis.

Authors:  Shun Li; David Mark Pritchard; Lu-Gang Yu
Journal:  Cancers (Basel)       Date:  2022-07-03       Impact factor: 6.575

4.  Anti-IL5 decreases the number of eosinophils but not the severity of dermatitis in Sharpin-deficient mice.

Authors:  Matthew L Renninger; Rosemarie E Seymour; Laurence O Whiteley; John P Sundberg; Harm Hogenesch
Journal:  Exp Dermatol       Date:  2009-07-23       Impact factor: 3.960

5.  Keratinocyte growth factor induces gene expression signature associated with suppression of malignant phenotype of cutaneous squamous carcinoma cells.

Authors:  Mervi Toriseva; Risto Ala-aho; Sirkku Peltonen; Juha Peltonen; Reidar Grénman; Veli-Matti Kähäri
Journal:  PLoS One       Date:  2012-03-12       Impact factor: 3.240

6.  Differential patterns of stromelysin-2 (MMP-10) and MT1-MMP (MMP-14) expression in epithelial skin cancers.

Authors:  E Kerkelä; R Ala-aho; J Lohi; R Grénman; V M-Kähäri; U Saarialho-Kere
Journal:  Br J Cancer       Date:  2001-03-02       Impact factor: 7.640

7.  MMP-13 regulates growth of wound granulation tissue and modulates gene expression signatures involved in inflammation, proteolysis, and cell viability.

Authors:  Mervi Toriseva; Matti Laato; Olli Carpén; Suvi T Ruohonen; Eriika Savontaus; Masaki Inada; Stephen M Krane; Veli-Matti Kähäri
Journal:  PLoS One       Date:  2012-08-07       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.